Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Life after Ponatinib Failure: Outcomes of Chronic and Accelerated Phase CML Patients Who Discontinued Ponatinib in the Salvage Setting

Prajwal Chaitanya Boddu, MD, Hagop M. Kantarjian, MD, Abdul Rashid Shah, MD, Gautam Borthakur, MD, Srdan Verstovsek, MD PhD, Guillermo Garcia-Manero, MD, Naval Daver, MD, Tapan Kadia, MD, Farhad Ravandi, MD, Nitin Jain, MD, Ahmad Alhuraiji, MD MRCP, Jan Burger, MD PhD, Steven M. Kornblau, MD, Sara Emogene Dellasala, BS, Sherry Pierce, BSN, BA, Elias J. Jabbour, MD, Jorge E. Cortes, MD

Blood (2016) 128 (22): 3073.

https://doi.org/10.1182/blood.V128.22.3073.3073

Published: 2016

Journal Articles

CpG-Stimulated Cytogenetic Abnormalities Associated with Shorter Time-to-First Treatment

Francesco Paolo Tambaro, MD PhD, Clelia Criscuolo, MD, Nitin Jain, MD, Alessandra Ferrajoli, MD, Philip A Thompson, MBBS, Jan Burger, MD PhD, Zeev Estrov, MD, Mimmo Ripaldi, MD, Hagop M. Kantarjian, MD, Susan M. O'Brien, MD, Michael Keating, MBBS, William G. Wierda, MD PhD

Blood (2016) 128 (22): 4351.

https://doi.org/10.1182/blood.V128.22.4351.4351

Published: 2016

Journal Articles

Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Steven Coutre, MD, John C. Byrd, MD, Peter Hillmen, Jacqueline C. Barrientos, MD, Paul M. Barr, Stephen Devereux, PhD FRCP, FRCPath, Tadeusz Robak, MD PhD, Thomas J. Kipps, MD, PhD, Anna Schuh, MDPhD, Carol Moreno, MD, Richard R. Furman, Jan Burger, MD PhD, Michael O'Dwyer, MD, Paolo Ghia, Rudolph Valentino, PharmD, Samuel Suzuki, MS, MBA, Joi Ninomoto, PharmD, Danelle F. James, MD MAS, Susan M. O'Brien, MD

Blood (2016) 128 (22): 4383.

https://doi.org/10.1182/blood.V128.22.4383.4383

Published: 2016

Journal Articles

Causes of Discontinuation and Long-Term Outcomes of Patients with CLL after Discontinuing Ibrutinib

Preetesh Jain, MBBS, MD DM, PhD, Philip A Thompson, MBBS, Michael Keating, MBBS, Zeev Estrov, MD, Alessandra Ferrajoli, MD, Nitin Jain, MD, Hagop M. Kantarjian, MD, Jan Burger, MD PhD, Susan M. O'Brien, MD, William G. Wierda, MD PhD

Blood (2016) 128 (22): 4390.

https://doi.org/10.1182/blood.V128.22.4390.4390

Published: 2016

Journal Articles

Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma

Blood (2016) 128 (22): 177.

https://doi.org/10.1182/blood.V128.22.177.177

Published: 2016

Journal Articles

Combination of Sorafenib and 5-Azacytidine in Older Patients with Untreated Acute Myeloid Leukemia with FLT3 -ITDmutation

Maro Ohanian, DO, Guillermo Garcia-Manero, MD, Elias J. Jabbour, MD, Naval Daver, MD, Gautam Borthakur, MD, Tapan M. Kadia, MD, Mark Brandt, BS, Sherry Pierce, BSN, BA, Jan Burger, MD PhD, Mary Ann Richie, Keyur Patel, MD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD

Blood (2016) 128 (22): 1611.

https://doi.org/10.1182/blood.V128.22.1611.1611

Published: 2016

Journal Articles

The Landscape of Dynamic Genetic Changes in Ibrutinib-Treated CLL

Dan A. Landau, MD PhD, Clare Sun, MD, Daniel Rosebrock, Mariela Campbell, Sarah E. M. Herman, PhD, Julia Hoellenriegel, MS, Mohammed Farooqui, Wandi Zhang, MD, Donna S. Neuberg, ScD, Dimitri Livitz, Ignaty Leshchiner, Gad Getz, PhD, Jan Burger, MD PhD, Adrian Wiestner, MD PhD, Catherine J Wu, MD

Blood (2016) 128 (22): 188.

https://doi.org/10.1182/blood.V128.22.188.188

Published: 2016

Journal Articles

Defining the Immune Checkpoint Landscape in the Bone Marrow and Peripheral Blood of Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2016) 128 (22): 2012.

https://doi.org/10.1182/blood.V128.22.2012.2012

Published: 2016

Journal Articles

Cardiovascular Events Among Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs)

Princy Yohannan Sam, MD, Hycienth Ahaneku, MDPhD, Graciela M. Nogueras-Gonzalez, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Gautam Borthakur, MD, William G. Wierda, MD PhD, Naval Daver, MD, Tapan Kadia, MD, Jan Burger, MD PhD, Sherry Pierce, BSN, BA, Courtney D DiNardo, MD, Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD

Blood (2016) 128 (22): 1919.

https://doi.org/10.1182/blood.V128.22.1919.1919

Published: 2016

Journal Articles

Outcomes of Ibrutinib Therapy By Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2)

Jennifer A. Woyach, MD, Peter Hillmen, Jennifer R. Brown, MD PhD, Steven E. Coutre, MD, Paul Barr, MD, Susan M. O'Brien, MD, Jacqueline C. Barrientos, MD, Stephen Devereux, PhD FRCP, FRCPath, Neil E. Kay, MD, Nishitha Reddy, MD MSCI, MBBS, Stephen Mulligan, MBBS, MD FRACP, FRCPA, Alessandra Tedeschi, Cathy Zhou, MS, Joi Ninomoto, PharmD, Danelle F. James, MD MAS, John C. Byrd, MD, Jan Burger, MD PhD

Blood (2016) 128 (22): 2041.

https://doi.org/10.1182/blood.V128.22.2041.2041

Published: 2016

Journal Articles

In Vivo Evidence of in Situ Cell Death Preferentially Occurring in CLL Patients with Minimal Lymphocytosis By the Diminished BCL2 and Loss of T Cell Support after Ibrutinib Treatment

Shih-Shih Chen, PhD, Steven Ham, Priyadarshini Ravichandran, Ileana D'Aloisio, Emily Kate Butera, Romi Lyallpuri, Yasmine Kieso, Jacqueline C. Barrientos, MD, Kanti R Rai, Jan Burger, MD PhD, Nicholas Chiorazzi, MD

Blood (2016) 128 (22): 5586.

https://doi.org/10.1182/blood.V128.22.5586.5586

Published: 2016

Journal Articles

Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Blood (2016) 128 (22): 234.

https://doi.org/10.1182/blood.V128.22.234.234

Published: 2016

Journal Articles

Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Susan M. O'Brien, MD, Richard R. Furman, MD, Steven E. Coutre, MD, Ian W. Flinn, MD PhD, Jan Burger, MD PhD, Kristie Blum, MD, Jeff Sharman, MD, William G. Wierda, MD PhD, Jeffrey Jones, MD MPH, Weiqiang Zhao, MD PhD, Nyla A. Heerema, PhD, Amy J. Johnson, PhD, Ying Luan, PhD, Danelle F. James, MD MAS, Alvina D. Chu, MD, John C. Byrd, MD

Blood (2016) 128 (22): 233.

https://doi.org/10.1182/blood.V128.22.233.233

Published: 2016

Journal Articles

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib

Preetesh Jain, Michael Keating, William Wierda, Zeev Estrov, Alessandra Ferrajoli, Nitin Jain, Binsah George, Danelle James, Hagop Kantarjian, Jan Burger, Susan O’Brien

Blood (2015) 125 (13): 2062–2067.

https://doi.org/10.1182/blood-2014-09-603670

Published: 2015

Journal Articles

Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL

Paolo Strati, Michael J. Keating, Susan M. O'Brien, Jan Burger, Alessandra Ferrajoli, Nitin Jain, Francesco Paolo Tambaro, Zeev Estrov, Jeffrey Jorgensen, Pramoda Challagundla, Stefan H. Faderl, William G. Wierda

Blood (2014) 123 (24): 3727–3732.

https://doi.org/10.1182/blood-2013-11-538116

Published: 2014

Includes: Supplemental data

Journal Articles

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT -3 internal tandem duplication mutation

Blood (2013) 121 (23): 4655–4662.

https://doi.org/10.1182/blood-2013-01-480228

Published: 2013

Includes: Supplemental data

Journal Articles

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

Alireza Eghtedar, Srdan Verstovsek, Zeev Estrov, Jan Burger, Jorge Cortes, Carol Bivins, Stefan Faderl, Alessandra Ferrajoli, Gautam Borthakur, Solly George, Peggy A. Scherle, Robert C. Newton, Hagop M. Kantarjian, Farhad Ravandi

Blood (2012) 119 (20): 4614–4618.

https://doi.org/10.1182/blood-2011-12-400051

Published: 2012

Journal Articles

Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia

Farhad Ravandi, Susan O'Brien, Jeffrey Jorgensen, Sherry Pierce, Stefan Faderl, Alessandra Ferrajoli, Charles Koller, Pramoda Challagundla, Sergernne York, Mark Brandt, Rajyalakshmi Luthra, Jan Burger, Deborah Thomas, Michael Keating, Hagop Kantarjian

Blood (2011) 118 (14): 3818–3823.

https://doi.org/10.1182/blood-2011-04-351502

Published: 2011

Journal Articles

Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia

Xavier C. Badoux, Michael J. Keating, Xuemei Wang, Susan M. O'Brien, Alessandra Ferrajoli, Stefan Faderl, Jan Burger, Charles Koller, Susan Lerner, Hagop Kantarjian, William G. Wierda

Blood (2011) 118 (8): 2085–2093.

https://doi.org/10.1182/blood-2011-03-341032

Published: 2011

Includes: Supplemental data

Journal Articles

Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia

Sameer A. Parikh, Michael J. Keating, Susan O'Brien, Xuemei Wang, Alessandra Ferrajoli, Stefan Faderl, Jan Burger, Charles Koller, Zeev Estrov, Xavier Badoux, Susan Lerner, William G. Wierda

Blood (2011) 118 (8): 2062–2068.

https://doi.org/10.1182/blood-2011-01-329177

Published: 2011

NARROW

Life after Ponatinib Failure: Outcomes of Chronic and Accelerated Phase CML Patients Who Discontinued Ponatinib in the Salvage Setting

CpG-Stimulated Cytogenetic Abnormalities Associated with Shorter Time-to-First Treatment

Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Causes of Discontinuation and Long-Term Outcomes of Patients with CLL after Discontinuing Ibrutinib

Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma

Combination of Sorafenib and 5-Azacytidine in Older Patients with Untreated Acute Myeloid Leukemia with FLT3 -ITDmutation

The Landscape of Dynamic Genetic Changes in Ibrutinib-Treated CLL

Defining the Immune Checkpoint Landscape in the Bone Marrow and Peripheral Blood of Patients with Chronic Lymphocytic Leukemia (CLL)

Cardiovascular Events Among Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs)

Outcomes of Ibrutinib Therapy By Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2)

In Vivo Evidence of in Situ Cell Death Preferentially Occurring in CLL Patients with Minimal Lymphocytosis By the Diminished BCL2 and Loss of T Cell Support after Ibrutinib Treatment

Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib

Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT -3 internal tandem duplication mutation

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia

Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia

Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only